Pharmaxis receives response letter from the FDA on Aridol application

29th Dec 09

Release Date: 29/12/2009 12:00am

Pharmaxis today announced it had received a Complete Response Letter from the U.S. Food and Drug Administration (FDA) in relation to its New Drug Application (NDA) for Aridol™ (mannitol inhalation powder).

 

Read full media release - pdf

Categories: News and Media